Belkin Re-introduces InvisiGlass: Reliable Screen Protection, Now Made With Recycled Glass
9.9.2024 22:38:00 CEST | Business Wire | Press release
The new screen protectors incorporate an impressive 60% post-industrial recycled (PIR) materials1
Belkin, a leading consumer electronics brand for 40 years, today announced its reimagined InvisiGlass screen protection collection, made with certified recycled glass. The InvisiGlass screen protection collection is now available on belkin.com for iPhone 16, iPhone 16 Plus, iPhone 16 Pro, and iPhone 16 Pro Max.
Belkin InvisiGlass is made with glass materials that are collected and recycled during the manufacturing process, certified by the Global Recycled Standard (GRS), and thoroughly tested to ensure the premium quality, durability, reliability and clarity that the brand name is known for.
Fortified with ion-exchange technology, InvisiGlass screen protectors are 62%2 more durable than tempered glass screen protectors without adding thickness or weight to provide best-in-class protection while maintaining the device’s natural look and feel.
The ScreenForce™ InvisiGlass collection includes:
- InvisiGlass – $29.99 USD – the new InvisiGlass is an upgrade to the original InvisiGlass Ultra material introduced in 2017. The new version is enhanced with recycled glass while still smooth to the touch and ultra-thin, preserving touchscreen sensitivity.
- InvisiGlass Blue Light Filter – $34.99 USD – incorporates industry-leading blue light reduction technology by Eyesafe to filter out 60% of blue light3. It is designed to support eye comfort for more enjoyable screen time, whether working, reading, or streaming.
- InvisiGlass Privacy – $34.99 USD – engineered with an added privacy filter to keep emails, webpages, texts and photos protected from prying eyes. It is the ideal solution for working on sensitive documents, banking online, or simply browsing the web or social media.
Belkin InvisiGlass Screen Protectors come in 100% recycled packaging4 using paper certified by the Forest Stewardship Council. The package contains a cleaning cloth, dust removal sticker to prevent air bubbles, and patented Easy Align tray for flawless alignment and fool-proof application.
For more information on Belkin InvisiGlass, see here: www.belkin.com/screenforce/sustainability
Pricing and Availability
The Belkin InvisiGlass Screen Protector collection for the new iPhone 16 lineup is available on belkin.com today for $29.99 – $34.99 USD and coming soon to major retailers worldwide.
Media kit is available for download HERE.
About Belkin
Belkin is a California-based accessories leader delivering award-winning power, protection, productivity, connectivity, and audio products over the last 40 years. Designed and engineered in Southern California and sold in more than 100 countries around the world, Belkin has maintained its steadfast focus on research and development, community, education, sustainability and most importantly, the people it serves. From our humble beginnings in a Southern California garage in 1983, Belkin has become a diverse, global technology company. We remain forever inspired by the planet we live on, and the connection between people and technology.
_________________________
1 Glass is made with a minimum of 60% post-industrial recycled glass and has been certified through GRS.
2 Based on internal tests, screen protectors can withstand up to 62% more force on average compared to conventional tempered glass screen protectors.
3 435-440 nm
4 Recycled plastic components include Easy Align tray, support tray, top protective film, and protective bags.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240909753989/en/
Contacts
Media Contact
Media Contact
Jen Wei
VP of Global Communications and Corporate Development
comms@belkin.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom